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Abstract
Acne is a dermatological disorder that can be more commonly seen in adolescents as well 
as younger patients. The pediatric acne is classified according to the age groups as neo-
natal acne, infantile acne, mid-childhood acne, and prepubertal acne. The presentation, 
pathogenesis, differential diagnosis, and treatment of the disease vary in each age group. 
Early diagnosis is important to prevent the scar formation and determine the underlying 
abnormalities.
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1. Introduction
Acne is one of the most common diseases in dermatology practice. Although acne has been 
known as a disease of the adolescents, it is also observed during the neonatal, infantile, 
mid-childhood, and prepubertal period. The severity of clinical findings varies mild to 
moderate in neonates but it could be more severe in different age groups. While the dis-
ease usually recovers spontaneously, in some severe scar formation cases, treatment should 
be needed. The treatment of acne is debate in these age groups, because of the possible 
adverse effects of the medications. Pediatric acne becomes a greater issue because it has a 
wide spectrum of differential diagnosis and could be associated with underlying systemic 
abnormalities [1–3].
© 2017 The Author(s). Licensee InTech. This chapter is distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is properly cited.
2. Classification of pediatric acne
2.1. Neonatal acne
2.1.1. Presentation and pathogenesis
Acne developing in newborns at birth or within 4-6 weeks immediately after birth is called 
neonatal acne [1]. It is more frequently seen in newborn boys than in girls [2]. The incidence 
of neonatal acne diagnosed based on the presence of comedone lesions is approximately 20% 
in newborns [3].
Although the etiopathogenesis is not exactly known, there are debates as to whether they 
are true acne or not [4]. A positive family history shows that there is role of genetic factors 
[2]. Sebaceous glands stimulated by maternal and neonatal androgens, increased seborrhea 
and Malassezia species are also regarded to be responsible from etiology [5]. In addition, 
there are findings that demonstrate the importance of maternal effects on newborn seba-
ceous glands. Maternal androgens stimulate sebaceous glands by transplacental transmis-
sion instead of transmission by maternal milk [6]. Sebum secreted in large amounts during 
the neonatal period decreases over time and the sizes of the sebaceous glands gradually 
decrease towards the end of the sixth month [2]. In particular, the role of enlargement 
in the zona reticularis of the fetal adrenal gland and the resulting increased production 
of β-hydroxysteroids have been emphasized. Increased β-hydroxysteroids also cause 
enlargement in the sebaceous glands, thereby, increasing sebum production. Additionally, 
β-hydroxysteroids secreted from the neonatal adrenal glands cause the sebaceous glands 
to become more sensitive to hormones in the future [3]. Luteinizing hormone and testos-
terone are high in neonatal boys between the sixth and twelfth months. Adrenal andro-
gens are responsible for neonatal acne in both newborn boys and girls. The presence of 
increased testicular androgens in males confirms why this disease is more frequently seen 
in boys [2, 3].
Neonatal acne is characterized by inflammatory lesions, such as papules and pustules, in 
addition to open and closed comedones, and rarely by nodules and cysts [1, 3]. It is most com-
monly seen in the cheeks and then in the forehead and less frequently in the neck and trun-
cal region [3]. Neonatal acne, which is characterized by self-limiting mild symptoms, rarely 
continues to the ninth to twelfth months and can transform to infantile acne. In the majority of 
the patients, there is no underlying disease. Following a detailed history and physical exami-
nation, endocrinological abnormalities should be further investigated in the presence of signs 
of virilization or other abnormal findings [1, 4].
Acneiform eruptions and infectious and noninfectious diseases, which can be sometimes seen 
during the neonatal period, are involved in the differential diagnosis. In the differential diag-
nosis, acne venenata infantum, acneiform drug reactions, chloracne, bacterial (Staphylococcus 
aureus, Listeria monocytogenes, beta hemolytic group B streptococcus), viral (Herpes simplex, 
Varicella zoster, cytomegalovirus), fungal (candidiasis, pityrosporum folliculitis), and parasitic 
(scabies) infections as infectious causes and erythema toxicum neonatorum, infantile acro-
pustulosis, milia, sebaceous gland hyperplasia, transient neonatal pustular melanosis, and 
pustular miliaria as noninfectious causes are often considered [5].
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2.1.2. Treatment
As neonatal acne is a mild and transient condition, it recovers spontaneously within four 
weeks and three months without scar formation. Rarely, it can persist up to six to twelve 
months [5]. Topical agents are often beneficial for treatment. The gel, lotion, and solution 
forms of topical antibiotics containing erythromycin and clindamycin and topical benzoyl 
peroxide can be used for inflammatory lesions and topical azelaic acid (20% cream) and topi-
cal retinoids (tretinoin 0.025-0.05% cream) can be used for comedonal lesions [2, 4]. If systemic 
treatment is required, an oral antibiotic such as erythromycin should be preferred [7].
The clinical characteristics of neonatal acne are summarized in Table 1.
2.1.3. Neonatal cephalic pustulosis
Neonatal cephalic pustulosis (NCP) is characterized by mild inflammatory papulopustular 
lesions and is differentiated from neonatal acne by the absence of comedones [1, 8]. In a study 
including 104 patients, the prevalence of NCP was approximately 25% in neonates [9]. It is 
thought to be due to the development of lipophilic yeasts in predisposed newborns who have 
increased sebum production. It has been demonstrated that Malassezia species, in particular, 
have a role in the etiopathogenesis of NCP [10, 11]. At birth, Malassezia colonization develops, 
depending on environmental factors, maternal contact, and the characteristics of newborn 
skin; it gradually increases within the first months of extrauterine life. In particular, Malassezia 
sympodialis and Malassezia globosa have a high prevalence. These fungi, which are found in 
the normal skin flora of infants, likely lead to follicular occlusion in predisposed infants who 
have increased sebum production. This, in turn, causes acneiform eruptions [8, 10, 12, 13]. 
However, the presence of negative mycological data in some NCP cases and the absence of 
NCP development in some culture-positive newborns lead us to believe that different fac-
tors also have an effect [1, 5]. There is a debate as to whether it is a hypersensitivity reaction 
developing against yeast or not [1]. In general, it is characterized by mild, transient lesions 
in the cheeks, chin, and forehead regions, which restrict themselves within a few weeks. As 
it is a self-limiting lesion, it does not usually require treatment. However, if needed, topical 
2% ketoconazole cream twice daily for 1 week is an appropriate treatment method [4, 8, 14].
Age at onset Birth–6 weeks
Clinical presentation Comedones, inflammatory papules and pustules, nodules, 
scarring
Differential diagnosis Neonatal cephalic pustulosis, bacterial-viral-fungal 
infections, erythema toxicum neonatorum, infantile 
acropustulosis, milia, sebaceous gland hyperplasia, 
transient neonatal pustular melanosis, pustular miliaria, 
chloracne, acne venenata infantum, acneiform drug 
eruptions
Treatment Recovers spontaneously without scar formationTopical 
azelaic acid, topical retinoids, topical antibioticOral 
antibiotic (erythromycin)





2.2.1. Presentation and pathogenesis
Infantile acne is a less common occurrence, compared to neonatal acne and it is observed 
between the first and twelfth months of extrauterine life. However, it can also develop 
in later periods, such as the 14th and 16th months [4, 15]. Infantile acne is more diffuse, 
inflamed, and persistent [3]. Similar to neonatal acne, infantile acne is also more common 
in males [2, 4]. Lesions are typically characterized by open and closed comedones, inflam-
matory papules and pustules, nodules and less commonly by scar forming cysts [1, 2, 3]. 
Infantile acne is most frequently seen on cheeks and less commonly seen on the chest and 
back (Figure 1) [1, 2]. Acne conglobata, which has primarily facial involvement and is clini-
cally similar to the adult form, is rarely seen [2]. Infantile acne, particularly conglobate 
infantile acne, may be associated with severe acne, which is seen during the adolescent 
period, and there is typically a positive family history of severe acne in these patients [16].
The causes of acne development during the infantile period are not so distinct. The presence 
of a positive family history emphasizes the role of genetic factors [8]. The general opinion 
tends toward the presence of sensitivity to the circulating adrenal and gonadal androgens. 
The release of adrenal androgens decreases close to age 1 and remains silent until the ages 
of 6-8. Zona reticularis which is the androgen-secreting part of fetal adrenal gland is large in 
both girls and boys and it gradually gets smaller beginning at age 1, during childhood period 
[8, 15]. It is thought that high levels of dehydroepiandrosterone (DHEA) and dehydroepian-
drosterone sulfate (DHEAS) secreted as a result of the continuation of fetal adrenal gland 
function after the neonatal period causes acne development by stimulating the sebaceous 
Figure 1. Infantile acne; an 8-month-old girl presented with closed comedones and inflammatory papules and pustules 
on her cheeks.
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glands [4, 8]. While there are high amounts of luteinizing hormone (LH) and testicular andro-
gen production until age one in boys, indeed, there is no testicular androgen production 
between age one and adrenarche. However, in girls, testosterone levels rapidly decrease at 
birth or within the first two weeks after birth. Thus, this situation explains why acne is more 
commonly seen in males [4, 8].
Most infantile acne is not associated with an underlying endocrinological abnormality. 
However, if the lesions are persistent, severe, and unresponsive to treatment, or if there is a find-
ing of hyperandrogenism in the physical examination of the infant (pubic hair, cliteromegaly, 
hirsutism, alopecia, accelerated growth, etc.), additional laboratory investigations for underly-
ing abnormalities should be performed [2, 7, 15]. Measurements of bone age, serological tests 
such as follicle-stimulating hormone (FSH), LH, free and total testosterone, DHEA, DHEAS, 
17β-hydroxyprogesterone, prolactin, and adrenocorticotropic hormone (ACTH) stimulation 
test should be performed [2, 4]. In rapidly developing infantile acne, attention should be given 
to virilizing tumors [17]. If the tests reveal an abnormality, the infant should be referred to pedi-
atric endocrinology.
In the differential diagnosis, acneiform eruptions developing due to the exposure are present. 
Acne venenata infantum or pomade acne can be seen due to comedogenic skin care prod-
uct forms such as pomades, creams, ointments, and oil form that are used by the parents; 
corticosteroid-induced acne is seen in the perioral, periocular, and infranasal areas due to 
topical, oral, and inhaler corticosteroids; chloracne is seen in the centrofacial region due to 
accidental exposure to chlorinated aromatic hydrocarbons. In addition to these conditions, 
neonatal acne, perioral dermatitis, milia, and miliaria should be also considered in the dif-
ferential diagnosis [4, 8].
2.2.2. Treatment
The course of the disease is variable. While the lesions disappear after one to two years in 
certain patients, they usually persist and most of the lesions recover after the age of four to 
five years. Less frequently, they can be active until puberty [3].
Parents of the patient with infantile acne should be warned about the fact that the disease can 
be persistent and severe acne can relapse during puberty [3]. The treatment of infantile acne 
is similar to the acne treatment in different age groups. Treatment varies according to the 
severity of the disease. In mild acne where comedone lesions are dominant, topical retinoids 
(tretinoin, adapalene) and/or the combination of topical benzoyl peroxide and topical anti-
biotic (erythromycin) can be used [5, 7, 18, 19]. Oral antibiotics can be used in more inflam-
matory lesions which are associated with papules, pustules, and nodules. The first choice, 
erythromycin, can be given in a dose of 125-250 mg, twice daily in this age group; if propi-
onibacterium acne is resistant to erythromycin, trimethoprim 100 mg could be given twice 
daily [2]. It is necessary to avoid oral tetracycline before age 8, as it could cause damage to the 
teeth and bones. Intralesional low dose triamcinolone acetonide (2.5 mg/mL), cryotherapy, 
and short-term topical corticosteroid therapy are options for acne associated with deep nod-
ules and cysts [3, 18, 20]. Oral isotretinoin can be used, if there is no response or if there is scar 




patients aged 12 and above in the treatment of nodulocystic acne [23]. In the literature, its use 
in children aged below five, at a dose of 0.36-2 mg/kg/day for 4-6 months, has been found to 
be effective; however, scar tissue occasionally remains [8, 22]. The optimal cumulative dose 
of isotretinoin during the infancy is unknown. Its use in young children is slightly more diffi-
cult, since it is found in soft gelatin capsules and inactivated by light and oxygen [21]. Thus, it 
should be opened under dim light and the daily recommended dose should be divided twice 
daily, by adding to food, such as butter, yogurt, a bread slice with jam, or milk. However, in 
this way, there is the possibility of inactivation or not taking the drug in recommended doses. 
Therefore, the capsule can be frozen in a viscous texture and cut in the required doses and 
given with a delicious food such as a candy bar [18, 21, 22]. This method prevents the wast-
ing of the drug and also facilitates its use by decreasing the poor taste of the drug. Patients 
should be carefully followed for possible side effects. The most common side effect is dryness 
of the mucous membranes and the skin [4]. As it may lead to changes in blood counts, liver 
functions, cholesterol, triglyceride levels, adverse skeletal effects such as calcification of liga-
ments and tendons, cortical hyperostosis, periosteal thickening, premature epiphyseal closure, 
decalcification, and possible osteoporosis, laboratory evaluations, and skeletal growth should 
be followed on regular intervals [8, 21, 24].
The clinical characteristics of infantile acne are summarized in Table 2.
2.3. Mid-childhood acne
2.3.1. Presentation and pathogenesis
Mid-childhood acne is observed between the 1 and 7 years of life [14]. Acne is quite rare dur-
ing this period. The children in this age group do not secrete significant amounts of adrenal or 
gonadal androgens. Androgen secretion of adrenals often disappears after the first year of life 
until age 7 (adrenarche). Then, zona reticularis regains function. Therefore, hyperandrogen-
ism should be investigated at the time of diagnosis [6, 8, 25].
Lesions are characterized by mixed comedones and inflammatory papules and pustules of the 
face, chest, and back [1].
Age at onset 6 weeks–12 months
Clinical presentation Comedones, inflammatory papules and pustules, nodules, 
less commonly by scar forming cysts, acne conglobata
Differential diagnosis Acne venenata infantum/pomade acne, corticosteroid 
induced acne, chloracne, neonatal acne, perioral dermatitis, 
milia, miliaria
Treatment Topical retinoids, topical benzoyl peroxide, topical 
antibiotic (erythromycin)Oral antibiotic (erythromycin, 
trimethoprim sulfamethoxazole)Intralesional low 
dose triamcinolone acetonide, cryotherapy, short-term 
topical corticosteroid therapy for nodules and cystsOral 
isotretinoin for scar formation lesions
Table 2. Infantile acne.
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In addition to premature adrenarche, which is a completely benign event, more severe condi-
tions such as congenital adrenal hyperplasia (CAH), gonadal and adrenal tumors, Cushing's 
syndrome, central precocious puberty, and exogenous androgen absorption should be excluded 
[2, 7, 15]. A careful physical examination should be done for the growth chart and the presence 
of findings related to hormonal abnormality. The bone age could be measured by radiological 
examination of the left hand or wrist [1, 2]. Laboratory tests such as serum total and free testos-
terone, DHEA, DHEAS, 17 alpha hydroxyprogesterone, FSH, LH, and prolactin levels should 
be measured to evaluate hormonal abnormalities [2]. If any abnormality is detected, it should be 
referred to pediatric endocrinology.
Inflamed keratosis pilaris, which is seen in the cheeks in atopic people, keratin cysts (miliaria), 
demodicosis, molluscum contagiosum, verruca plana, idiopathic facial aseptic granuloma, 
pseudoacne of the nasal crease, perioral dermatitis, and angiofibroma should be considered 
in the differential diagnosis of mid-childhood acne [7, 15, 26, 27]. In the literature, dactinomy-
cin-induced acne has been reported in this age group [28].
2.3.2. Treatment
Its treatment depends on the underlying endocrinological abnormality. However, if neces-
sary, topical treatments and oral antibiotics are similar to infantile acne [2, 8].
The clinical characteristics of mid-childhood acne are summarized in Table 3.
2.4. Prepubertal acne
2.4.1. Presentation and pathogenesis
Acne, which is observed between the ages of 7 and 11, is called prepubertal acne and its inci-
dence has increased in recent years [15]. Contrary to expectations, acne can occur prior to 
pubertal signs. There is a genetic predisposition in these patients. An increased early-onset 
acne can be an initial finding of pubertal development rather than age [2]. Prepubertal acne is 
a consequence of normal adrenarche, which develops depending on adrenal gland maturation 
[7]. Acne development in premenarche girls has been reported as 61-71.3% [29, 30]. The most 
common presentation is comedonal lesions in the center region of the forehead. Inflammatory 
papules and pustules can be seen in the central of the face and sometimes in the ear concha, 
Age at onset 1–7 years
Clinical presentation Comedones, inflammatory papules and pustules
Differential diagnosis Inflamed keratosis pilaris, keratin cysts, demodicosis, 
molluscum contagiosum, verruca plana, idiopathic facial 
aseptic granuloma, perioral dermatitis, angiofibroma
Treatment Depends on the underlying abnormalityTopical 
retinoids, topical benzoyl peroxide, topical antibiotic 
(erythromycin)Oral antibiotic (erythromycin, 
trimethoprim)Oral isotretinoin




chest, and back [1]. Advancing pubertal maturation was found to be correlated with the preva-
lence and severity of acne in both boys and girls [29, 31]. There are two components of pubertal 
development. The first component is adrenarche, which is the initiation of androgen synthesis 
(DHEA, DHEAS) together with the maturation of the adrenal gland at the age of 6-7 years 
in girls and at the age of 7-8 years in boys. DHEA and DHEAS lead to the development of 
seborrhea, odor, terminal and sexual hair, and acne. Excessive androgen production could 
be related to adrenal hyperandrogenism, congenital adrenal hyperplasia, Cushing's disease, 
21-hydroxylase deficiency, and androgen-secreting tumors. Furthermore, true puberty, the sec-
ond component, is the maturation of the ovary and testis under the effect of the hypothalamo-
pituitary-adrenal (HPA) axis. Androgen secretion from the gonads is low during this period of 
life. Excess ovarian androgens can be due to benign and malignant tumors; however, they are 
most frequently associated with polycystic ovary syndrome (PCOS) [2, 5, 7].
In a 5-year cohort study performed on girls, acne lesions increased with age and maturation 
was reported. The most common type of lesions was comedone. On the other hand, no ethnic 
differences were observed. The study revealed that the girls who had severe acne had more 
comedone and inflammatory lesions beginning from age 10 and 2.5 years before menarche 
and they had earlier menarche. High levels of serum DHEAS, free and total testosterone sug-
gest that it could be an initiator of severe long-term disease [32].
In general, there is no need to further research prepubertal acne. If there is persistent acne 
that is unresponsive to treatment or findings suggesting androgen excess are detected, 
possible endocrinological abnormalities should be suspected. Tanner stages demonstrat-
ing pubertal development should be measured, a hand film should be taken for bone age, 
and serum-free and total testosterone, DHEAS levels and ratio of LH to FSH should be 
measured [8, 15, 25, 33].
Its differential diagnosis is similar to mid-childhood acne. In addition, the side effects of drugs 
such as corticosteroids and anticonvulsants, prepubertal hidradenitis suppurativa, adenoma 
sebaceum, keratosis pilaris, and inflamed keratin cysts should be considered in the differen-
tial diagnosis [2, 34–36].
2.4.2. Treatment
Nonetheless, data related to acne medications during the preadolescent period are limited. 
Most of the acne drugs are approved for age 12 and above. Its treatment is similar to infantile 
and mid-childhood acne. Topical retinoids (tretinoin 0.04% microsphere gel), benzoyl perox-
ide, and antibiotics can be used in mild to moderate comedonal and inflammatory acne. Oral 
antibiotics and oral isotretinoin may also be required in more severe scar forming lesions. As 
an oral antibiotic, erythromycin and its derivatives, trimethoprim, and cephalexin should be 
preferred. Tetracycline and its derivatives should be avoided, as these agents may produce 
dental enamel staining. Oral contraceptives or antiandrogens such as spironolactone can be 
used for PCOS and low-dose corticosteroids can be used for CAH. However, oral contracep-
tives should be used carefully due to the risk of premature epiphyseal closure [2, 5, 37].
The clinical characteristics of prepubertal acne are summarized in Table 4.
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